In chronic kidney disease, the pivotal FLOW trial demonstrated that semaglutide 1 mg reduced the risk of major kidney events by 24% in patients with type 2 diabetes and CKD, resulting in a dedicated indication in this population
Niu, K., Bao, T., Gao, L., Ru, M., Li, Y., Jiang, L., Ye, C., Wang, S., & Wu, X
80 A great fit for budget-conscious patients who want straightforward, no-hassle care
If you experience any of the following, seek immediate medical attention: Pancreatitis : Severe, persistent stomach pain that may spread to your back could be a sign of pancreatitis
Ongoing research may teach us more about whether GLP-1 receptor agonists can influence Alzheimers disease progression or neurodegenerative risk
NjeiBAl-AjlouniYLemosSYUgwendumDAmeyawPNjeiLPet al